MX2023006652A - Derivados de amina-indol-3-ciclica como agentes serotonergicos para el tratamiento de trastornos del snc. - Google Patents

Derivados de amina-indol-3-ciclica como agentes serotonergicos para el tratamiento de trastornos del snc.

Info

Publication number
MX2023006652A
MX2023006652A MX2023006652A MX2023006652A MX2023006652A MX 2023006652 A MX2023006652 A MX 2023006652A MX 2023006652 A MX2023006652 A MX 2023006652A MX 2023006652 A MX2023006652 A MX 2023006652A MX 2023006652 A MX2023006652 A MX 2023006652A
Authority
MX
Mexico
Prior art keywords
cyclic amine
indole derivatives
treatment
cns disorders
serotonergic agents
Prior art date
Application number
MX2023006652A
Other languages
English (en)
Spanish (es)
Inventor
Abdelmalik Slassi
Joseph Araujo
Guy Higgins
Original Assignee
Mindset Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mindset Pharma Inc filed Critical Mindset Pharma Inc
Publication of MX2023006652A publication Critical patent/MX2023006652A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2023006652A 2020-12-07 2021-12-07 Derivados de amina-indol-3-ciclica como agentes serotonergicos para el tratamiento de trastornos del snc. MX2023006652A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063122181P 2020-12-07 2020-12-07
PCT/CA2021/051755 WO2022120475A1 (en) 2020-12-07 2021-12-07 3-cyclic amine-indole derivatives as serotonergic agents for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
MX2023006652A true MX2023006652A (es) 2023-09-21

Family

ID=81973031

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006652A MX2023006652A (es) 2020-12-07 2021-12-07 Derivados de amina-indol-3-ciclica como agentes serotonergicos para el tratamiento de trastornos del snc.

Country Status (10)

Country Link
US (1) US20240051978A1 (https=)
EP (1) EP4255913A4 (https=)
JP (1) JP2023553094A (https=)
KR (1) KR20230117597A (https=)
CN (1) CN116917305A (https=)
AU (1) AU2021394129A1 (https=)
CA (1) CA3201080A1 (https=)
IL (1) IL303467A (https=)
MX (1) MX2023006652A (https=)
WO (1) WO2022120475A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
US20240286998A1 (en) * 2021-06-02 2024-08-29 Saint Joseph's University Fluorinated tryptamine compounds, analogues thereof, and methods using same
IL313455A (en) 2021-12-15 2024-08-01 Delix Therapeutics Inc Phenoxy and benzyloxy modified psychroplastogens and their uses
WO2023114472A1 (en) * 2021-12-16 2023-06-22 Icahn School Of Medicine At Mount Sinai Heterocyclic compounds as 5ht2a biased agonists
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US20250325516A1 (en) * 2022-07-08 2025-10-23 Institut Curie Serotonin analogues for use in treating metalloptosis-associated disorders
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789402A (en) * 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US6133287A (en) * 1998-03-24 2000-10-17 Allelix Biopharmaceuticals Inc. Piperidine-indole compounds having 5-HT6 affinity
GB9810886D0 (en) * 1998-05-13 1998-07-22 Lilly Industries Ltd Pharmaceutical compounds
ATE375990T1 (de) * 1999-04-21 2007-11-15 Nps Allelix Corp Piperidin-indol derivate mit 5-ht6 affinität
WO2004069828A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation ピペリジン化合物およびその医薬用途
WO2005066157A1 (en) * 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
EP1984351A1 (en) * 2006-02-17 2008-10-29 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
EP2464227A4 (en) * 2009-08-10 2013-02-20 Galenea Corp COMPOUNDS AND METHODS OF USE
AU2021373520A1 (en) * 2020-11-06 2023-06-29 Mynd Life Sciences Inc. A method of treating depression by immune modulation

Also Published As

Publication number Publication date
CA3201080A1 (en) 2022-06-16
WO2022120475A1 (en) 2022-06-16
AU2021394129A1 (en) 2023-07-20
KR20230117597A (ko) 2023-08-08
EP4255913A4 (en) 2024-11-06
US20240051978A1 (en) 2024-02-15
IL303467A (en) 2023-08-01
JP2023553094A (ja) 2023-12-20
CN116917305A (zh) 2023-10-20
EP4255913A1 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
MX2023006652A (es) Derivados de amina-indol-3-ciclica como agentes serotonergicos para el tratamiento de trastornos del snc.
PH12022551981A1 (en) Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
MX2023010316A (es) Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.
MX2025001439A (es) Dímeros de 3-etilamino-indol como agentes serotoninérgicos útiles para el tratamiento de trastornos relacionados con los mismos
MX2024012865A (es) Derivados de indolina como agentes serotoninergicos utiles para el tratamiento de trastornos relacionados con los mismos
BR112022015379A2 (pt) Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc
MX2023013245A (es) Rescorcinoles, metodos para su fabricacion, y usos de los mismos.
MA50391B1 (fr) Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires
JO2907B1 (en) Pyridine derivatives 1, 2, 4 trisolo [4, 3-A] and their uses as positive LLs for 2MGLUR receptors
PH12012502212A1 (en) Nitrogen heterocyclic compounds usefulas pde10 inhibitors
JOP20170067B1 (ar) معدِّلات مختلفة الشكل الفراغي لمستقبلات أسيتيل كولين النيكوتينية
MX2011011963A (es) Derivados de 7-aril-1,2,4-triazolo[4,3-a]piridina y uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2).
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
PH12022500021A1 (en) Il-17a modulators
PH12012501863A1 (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
PH12022552773A1 (en) Tetrahydroisoquinoline compounds as nrf2 activators
PH12022500015A1 (en) Ccr6 receptor modulators
PH12019502462A1 (en) Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors
WO2022115944A8 (en) Carboxylated psilocybin derivatives and methods of using
MX2025001465A (es) Dimeros de 3-pirrolidina-indol como agentes serotoninergicos utiles para el tratamiento de trastornos relacionados con los mismos
MX2024014435A (es) Compuestos heterociclicos y heteroarilo para el tratamiento de la enfermedad de huntington
ZA202211465B (en) Tetrahydroisoquinoline compounds as nrf2 activators
MX2021002017A (es) Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.
PH12022552553A1 (en) Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity
PH12021552680A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases